Hypercalcemia Treatment Market

Industry Outlook

The global hypercalcemia treatment market will reach US$ 23,707.8 Mn by 2026 from US$ 9,544.1 Mn in 2017, growing at a CAGR of 10.7% during the forecast period from 2018 to 2026. Hypercalcemia is a condition characterized by the elevated levels of serum calcium ranging above 2.6 mmol/L. The disorder is predominantly associated with two main causes including hypercalcemia of malignancy (HCM) and primary hyperparathyroidism. The disorder occurs in 10% to 20% of the cancer patients, prominently in the breast and lung cancer patients. Furthermore, other factors responsible for hypercalcemia are hereditary factors, severe dehydration, medications, and supplements. The global hypercalcemia treatment market will surge during the forecast period pertaining to the rising number of cancer patients, growing prevalence of hyperparathyroidism-related hypercalcemia, and availability of appropriate drug treatment therapies. Furthermore, rising incidence of multiple myeloma, availability of drug therapy alternatives over surgeries and favorable reimbursement policies in developed countries including the United States expected to fuel global market.

As generics dominates the market, label extension of the drugs for the treatment of more indications further expected to contribute to the growth of the market. The key market players are particularly focusing on the chronic kidney disease (CKD) along with the parathyroidism. For instance, US FDA approved a drug manufactured by OPKO Health for the treatment of secondary hyperparathyroidism in adults with CKD. Such approvals will propel the growth of global hypercalcemia market.

Market Synopsis

Bisphosphonates expected to retain major market share during the forecast period

Bisphosphonates is the major segment capturing over 65% of market value share. Bisphosphonates are used to prevent the loss of bone density. Due to the high preference of bisphosphonates, the segment will retain its supremacy in the market during the forecast period. Furthermore, the usage of combination therapy for the treatment of hypercalcemia is increasing, which combines two or more drugs from same or different classes. The high preference of combination therapy in developed country further fuels the growth of bisphosphonates market as these drugs are used predominantly in combination therapy with other drugs and therapies. For instance, many researchers and physicians are evaluating the use of combination of pamidronate and calcitonin. Denusomab market segment will be the fastest growing market segment during the forecast period followed by calcitonin. The aforementioned treatment pattern adopted by physicians is expected to catalyze the growth of hypercalcemia drugs market.

Asia Pacific to Experience Lucrative Growth with Double Digit CAGR during the Forecast Period

The Asia Pacific expected to witness lucrative growth during the forecast period owing to high awareness and rising adoption of the hypercalcemia treatment drugs. Furthermore, increasing prevalence of hyperparathyroidism-related hypercalcemia and growing incidence of multiple myeloma in the region expected to fuel the market. Additionally, the rising accessibility of drug therapies and favorable reimbursement policies in the developing countries further contributes to the double-digit growth of the Asia Pacific market.

In 2017, North America dominated the hypercalcemia treatment market with over 34% of the market share, in terms of market value. The United States expected to dominate the North America market due to high awareness regarding hypercalcemia and associated disorders. Furthermore, growing prevalence of malignancy-related hypercalcemia among cancer patients will further catalyze the growth of the North America hypercalcemia market.

Approval of Promising Pipeline Candidates Expected to Fuel the Market Growth

The global hypercalcemia treatment market is highly fragmented due to the presence of numerous players. However, some of the players dominated the market attributing to the development of effective drugs, novel product launches, and strategic market initiatives. Furthermore, the unmet needs of the disease compel manufacturers to focus on R&D and develop products that are more efficient. For instance, Kyowa Hakko Kirin Co., Ltd. has completed phase III clinical trials for KHK7580 and filled a NDA (New Drug Application) in Japan. Furthermore, the manufacturers is developing another candidate, KRN1493, for secondary hyperparathyroidism. Expected approval of such promising candidates will fuel the market during the forecast period. Additionally, key players in hypercalcemia market include Novartis AG, Amgen, Inc., Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin, OPKO Health, Merck & Co., Abbive, Inc., and Pfizer, Inc.

Historical & Forecast Period

The hypercalcemia market is scrutinized considering 2017 as the base year for the research and CAGRs are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This holistic research study on hypercalcemia treatment market present the current market dynamics and outlook. The research study is conducted at granular level by segmenting the market in terms of drug class and geography.

This research study further elucidates the key qualitative market assessment parameters including key market trends, DROs, to assist in holistic understanding of global hypercalcemia treatment market. Additionally, the major players are mapped graphically based on their business strength, market strategies and product offering. The research study further provides attractive investment proposition based on the extensive geographical research. Major manufacturers profiled in the report include AbbVie, Inc., Merck & Co., OPKO Health, Novartis AG, Amgen, Inc., Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin and Pfizer, Inc.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Market Segmentation
1.3 Research Scope
1.4 Research Methodology
1.4.1 Phase I – Secondary Research
1.4.2 Phase II – Primary Research
1.4.3 Phase III – Expert Panel Review
1.4.4 Assumptions

Chapter 2 Executive Summary
2.1 Global HT Market Portraiture
2.2 Global HT Market, by Drug Class, 2017 (US$ Mn)
2.3 Global HT Market, by Geography, 2017 (US$ Mn)

Chapter 3 Global Hypercalcemia Treatment (HT) Market: Dynamics & Future Outlook
3.1 Market Overview
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Adoption of Combination Therapy in Treatment of Hypercalcemia
3.2.1.2 Rising Prevalence of Malignancy and Hyperparathyroidism-related Hypercalcemia
3.2.2 Challenges
3.2.2.1 Challenge 1
3.2.3 Opportunities
3.2.3.1 Opportunity 1
3.3 Attractive Investment Proposition, by Geography, 2017
3.4 Competitive Landscape, by Key Players, 2017

Chapter 4 Global Hypercalcemia Treatment (HT) Market, by Drug Class, 2016-2026 (US$ Mn)
4.1 Overview
4.2 Bisphosphonates
4.2.1 Clodronate
4.2.2 Etidronate
4.2.3 Ibandronate
4.2.4 Pamidronate
4.2.5 Zoledronic acid
4.3 Calcimimetic Agents
4.4 Calcitonin
4.5 Denusomab
4.6 Glucocorticoids
4.7 Pipeline Analysis
4.7.1 Phase III
4.7.1.1 KHK7580
4.7.2 Phase II & I (Tabular Information)

Chapter 5 Global Hypercalcemia Treatment (HT) Market, by Geography, 2016-2026 (US$ Mn)
5.1 Overview
5.2 North America HT Market, 2016–2026 (US$ Mn)
5.2.1 North America HT Market, by Drug Class, 2016–2026 (US$ Mn)
5.2.2 North America HT Market, by Country, 2016–2026 (US$ Mn)
5.2.2.1 United States
5.2.2.2 Canada
5.3 Europe HT Market, 2016–2026 (US$ Mn)
5.3.1 Europe HT Market, by Drug Class, 2016–2026 (US$ Mn)
5.3.2 Europe HT Market, by Country/Region, 2016–2026 (US$ Mn)
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 Rest of Europe
5.4 Asia Pacific HT Market, 2016–2026 (US$ Mn)
5.4.1 Asia Pacific HT Market, by Drug Class, 2016–2026 (US$ Mn)
5.4.2 Asia Pacific HT Market, by Country/Region, 2016–2026 (US$ Mn)
5.4.2.1 Japan
5.4.2.2 China
5.4.2.3 Rest of Asia Pacific
5.5 Latin America HT Market, 2016–2026 (US$ Mn)
5.5.1 Latin America HT Market, by Drug Class, 2016–2026 (US$ Mn)
5.5.2 Latin America HT Market, by Country/Region, 2016–2026 (US$ Mn)
5.5.2.1 Brazil
5.5.2.2 Mexico
5.5.2.3 Rest of LATAM
5.6 Middle East & Africa HT Market, 2016–2026 (US$ Mn)
5.6.1 Middle East & Africa HT Market, by Drug Class, 2016–2026 (US$ Mn)
5.6.2 Middle East & Africa HT Market, by Region, 2016–2026 (US$ Mn)
5.6.2.1 GCC
5.6.2.2 Rest of MEA

Chapter 6 Company Profiles
6.1 Amgen, Inc.
6.1.1 Business Description
6.1.2 Financial Information
6.1.3 Product Portfolio
6.1.4 Key Developments
6.2 Bayer Pharma AG
6.3 Cipla, Inc.
6.4 Dr. Reddy’s Laboratories, Ltd.
6.5 Mylan N.V.
6.6 Novartis AG
6.7 Pfizer, Inc.
6.8 Sun Pharmaceutical Industries, Ltd.

List of Figures

FIG. 1 Market Segmentation: Global Hypercalcemia Treatment (HT) Market
FIG. 2 Global HT Market: Research Methodology
FIG. 3 Global HT Market, by Drug Class, 2017 (US$ Mn)
FIG. 4 Global HT Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition, by Geography, 2017
FIG. 6 Competitive Analysis: Global HT Market, by Key Players, 2017
FIG. 7 Global Clodronate Market for HT, 2016–2026 (US$ Mn)
FIG. 8 Global Etidronate Market for HT, 2016–2026 (US$ Mn)
FIG. 9 Global Ibandronate Market for HT, 2016–2026 (US$ Mn)
FIG. 10 Global Pamidronate Market for HT, 2016–2026 (US$ Mn)
FIG. 11 Global Zoledronic acid Market for HT, 2016–2026 (US$ Mn)
FIG. 12 Global Calcimimetic Agents Market for HT, 2016–2026 (US$ Mn)
FIG. 13 Global Calcitonin Market for HT, 2016–2026 (US$ Mn)
FIG. 14 Global Denusomab Market for HT, 2016–2026 (US$ Mn)
FIG. 15 Global Glucocorticoids Market for HT, 2016–2026 (US$ Mn)
FIG. 16 Global KHK7580 Market for HT, 2016–2026 (US$ Mn)
FIG. 17 U.S. HT Market, 2016–2026 (US$ Mn)
FIG. 18 Canada HT Market, 2016–2026 (US$ Mn)
FIG. 19 U.K. HT Market, 2016–2026 (US$ Mn)
FIG. 20 Germany HT Market, 2016–2026 (US$ Mn)
FIG. 21 Rest of Europe HT Market, 2016–2026 (US$ Mn)
FIG. 22 Japan HT Market, 2016–2026 (US$ Mn)
FIG. 23 China HT Market, 2016–2026 (US$ Mn)
FIG. 24 Rest of Asia Pacific HT Market, 2016–2026 (US$ Mn)
FIG. 25 Brazil HT Market, 2016–2026 (US$ Mn)
FIG. 26 Mexico HT Market, 2016–2026 (US$ Mn)
FIG. 27 Rest of Latin America HT Market, 2016–2026 (US$ Mn)
FIG. 28 GCC HT Market, 2016–2026 (US$ Mn)
FIG. 29 Rest of Middle East & Africa HT Market, 2016–2026 (US$ Mn)

List of Tables

TABLE 1 Global Hypercalcemia Treatment (HT) Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 2 Global Bisphosphonates Market for HT, 2016–2026 (US$ Mn)
TABLE 3 Global HT Market, by Geography, 2016–2026 (US$ Mn)
TABLE 4 Hypercalcemia Phase II & I Drugs Tabular Information
TABLE 5 North America HT Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 6 North America HT Market, by Country, 2016–2026 (US$ Mn)
TABLE 7 Europe HT Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 8 Europe HT Market, by Country, 2016–2026 (US$ Mn)
TABLE 9 Asia Pacific HT Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 10 Asia Pacific HT Market, by Country, 2016–2026 (US$ Mn)
TABLE 11 Latin America HT Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 12 Latin America HT Market, by Country, 2016–2026 (US$ Mn)
TABLE 13 Middle East & Africa HT Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 14 Middle East & Africa HT Market, by Region, 2016–2026 (US$ Mn)
TABLE 15 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Bayer Pharma AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Cipla, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Dr. Reddy’s Laboratories, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Mylan N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Sun Pharmaceutical Industries, Ltd: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)